Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases
Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases
复制标题
DOI：
10.21873/invivo.11503
复制
发表时间：
2019-03-01
期刊：
影响因子：
2.3
通讯作者：
Kijima, Takashi
中科院分区：
文献类型：
--
作者：
Akano, Yumiko;Kuribayashi, Kozo;Kijima, Takashi
背景/目的：Nivolumab是一种用于晚期非小细胞肺癌（NSCLC）的免疫检查点抑制剂。我们通过分析治疗前晚期或复发NSCLC患者的反应因子、不良反应（AE）和治疗后情况来研究nivolumab的安全性和有效性。患者和方法：2015年12月至2018年1月，对79例预处理NSCLC患者给予Nivolumab （3mg /kg）。尼武单抗的疗效和AE分别采用实体肿瘤反应评价标准和通用术语标准进行评估。结果：在治疗效果为部分缓解的病例中，无进展生存期（PFS）显著延长（p=0.0004）。5例（6.3%）发生3-4级ae。与非皮疹组相比，皮疹组和停止纳武单抗治疗的患者的PFS显著延长。结论：皮疹患者可长期存活。纳武单抗给药后立即给予治疗效果似乎有利于生存。
Background/Aim: Nivolumab is an immune checkpoint inhibitor for advanced non-small cell lung cancer (NSCLC). We investigated the safety and efficacy of nivolumab by analyzing the response factor, adverse effects (AE), and the post-treatment condition of pretreated advanced or recurrent NSCLC patients. Patients and Methods: Nivolumab (3 mg/kg) was administered to 79 pre-treated NSCLC patients from December 2015 to January 2018. Nivolumab efficacy and AE were assessed using the Response Evaluation Criteria in Solid Tumors and the Common Terminology Criteria, respectively. Results: Progression free survival (PFS) was significantly prolonged in cases where the therapeutic effect of the pretreatment was a partial response (p=0.0004). Five cases (6.3%) experienced grade 3-4 AEs. PFS was significantly prolonged in the skin rash group versus the non-skin rash group, and in patients where nivolumab treatment was discontinued. Conclusions: Long-term survival was observed in patients with skin rash. Therapeutic effect of nivolumab immediately following its administration appears to be favorable for survival.